Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

ClinicalTrials.gov ID: NCT04090398

Public ClinicalTrials.gov record NCT04090398. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well radium-223 dichloride and paclitaxel work in treating patients with advanced breast cancer that has spread to the bones. Radium-223 dichloride is a radioactive drug that behaves in a similar way to calcium and collects in cancer that has spread to the bones (bone metastases). The radioactive particles in radium-223 dichloride act on bone metastases, killing the tumor cells and reducing the pain that they can cause. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radium-223 dichloride and paclitaxel may work better in treating patients with metastatic breast cancer compared to paclitaxel alone.

Study identification

NCT ID
NCT04090398
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Enrollment
70 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 3, 2020
Primary completion
Jun 29, 2027
Completion
Jun 29, 2027
Last update posted
Jul 30, 2026

2020 – 2027

United States locations

U.S. sites
30
U.S. states
15
U.S. cities
29
Facility City State ZIP Site status
University of Alabama at Birmingham Cancer Center Birmingham Alabama 35233
City of Hope Comprehensive Cancer Center Duarte California 91010
UC Irvine Health/Chao Family Comprehensive Cancer Center Orange California 92868
University of California Davis Comprehensive Cancer Center Sacramento California 95817
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136
UM Sylvester Comprehensive Cancer Center at Kendall Miami Florida 33176
UM Sylvester Comprehensive Cancer Center at Plantation Plantation Florida 33324
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637
UC Comprehensive Cancer Center at Silver Cross New Lenox Illinois 60451
University of Chicago Medicine-Orland Park Orland Park Illinois 60462
University of Kansas Clinical Research Center Fairway Kansas 66205
University of Kansas Cancer Center Kansas City Kansas 66160
University of Kansas Cancer Center-Overland Park Overland Park Kansas 66210
University of Kansas Health System Saint Francis Campus Topeka Kansas 66606
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536
Wayne State University/Karmanos Cancer Institute Detroit Michigan 48201
Weisberg Cancer Treatment Center Farmington Hills Michigan 48334
University of Kansas Cancer Center - North Kansas City Missouri 64154
University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri 64064
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City Missouri 64116
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire 03756
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903
Laura and Isaac Perlmutter Cancer Center at NYU Langone New York New York 10016
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
University of Virginia Cancer Center Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04090398, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2026 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04090398 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →